UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

Inclusion Criteria: * (1) Age ≥18 years old (including the threshold value), gender is not limited; * (2) Expected survival time ≥3 months; * (3) ECOG score 0\~2 points; * (4) Subjects who meet the clinical diagnostic criteria and are clearly diagnosed as malignant solid tumor by pathology and failed by conventional treatment; * (5) immunohistochemistry (IHC) staining of tumor tissue samples showed that B7-H3 on tumor cell membrane surface was 1+ or above; while immunohistochemistry (IHC) staining of tumor cell membrane was ≥50%; * (6) The presence of at least one measurable lesion according to RECIST version 1.1; * (7) Blood cell analysis (no transfusion treatment within 3 days) : Hemoglobin (Hb) ≥80g/L; Absolute neutrophil count ≥1.5 x 10\^9/L; Platelet count (PLT) ≥75×10\^9/L; * (8) Kidney, liver, heart and lung function meet the following requirements: Creatinine clearance ≥60 ml/min or serum creatinine ≤ 1.5× upper limit of normal (ULN); Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤1.5 x ULN, Total bilirubin (TBL) ≤1.5×ULN (If the elevation of ALT and AST can be reasonably attributed to the presence of metastatic lesions in the liver, AST and ALT can be increased to 5×ULN, TBL can be increased to 3×ULN; Serum albumin ≥3.0g/dL; No clinically significant Electrocardiogram (ECG) results with left ventricular ejection fraction ≥ 50%; Blood oxygen saturation \> 95% in the non-oxygenated state; * (9) The patient himself/herself and/or his/her guardian and/…